Tentative agenda for 2-day meeting (Talks 10-30 min)

- HCL: 50 years of history (Golomb, Harvey)
- Diagnosis of HCL
  - Diagnosis by morphology including differential diagnosis (Jaffe, Elaine)
  - Pathological diagnosis of HCL (Sharpe, Robert)
  - Diagnosis by flow cytometry (Stetler-Stevenson, Maryalice)
  - Differential diagnosis of HCL with HCL-variant and typical and diffuse red pulp SMZL. (Matutes, Estella)
- Historical treatments of HCL
  - Splenectomy and interferon, past and current uses (Rai, Kanti)
- Treatment of HCL with pentostatin
  - Mechanism of action of purine analogs (Cawley, John)
  - Results of pentostatin in HCL compared to other B- & T-cell malignancies (Ho, Anthony)
  - Long term results of pentostatin and cladribine for HCL and their comparison (Dearden, Claire)
  - Current uses of pentostatin in the management of HCL (Grever, Michael)
- Treatment of HCL with cladribine
  - Development of cladribine at Scripps for HCL and current results (Saven, Alan)
  - Cladribine treatment for HCL in Europe (Pier Luigi Zinzani)
  - Investigation of alternate methods of administration (Lauria, Francesco)
  - Sensitivity to purine analogs cladribine and pentostatin and patterns of response (Johnston, James)
  - Pharmacokinetics of purine analogs and other treatments for HCL (Juliusson, Gunnar)
- Toxicity of purine analogs
  - Neurotoxicity and 2nd malignancy (Cheson, Bruce)
  - Infections with HCL and purine analogs (Kraut, Eric)
  - 2nd malignancies in patients with HCL (Hisada, Michie)
- Uncommon problems in HCL
  - Management of HCL variant (Robak, Tadeusz)
  - Unusual Manifestations of HCL (Polliack, Aaron)
- Implications of minimal residual disease (MRD) in HCL
  - CR with and without MRD: Criteria by bone marrow immunohistochemistry (Noel, Pierre)
  - Clinical data from cladribine testing using immunohistochemistry (Tallman, Martin)
  - High-sensitivity PCR tests for HCL MRD (Raffeld, Mark)
  - Tumor markers in HCL (Janik, John)
- Treatment of HCL with rituximab
• Rituximab as a single agent for HCL, mechanisms of action and results (Thomas, Deborah)
• Rituximab combined with cladribine for HCL (Ravandi, Farhad)
• Rituximab combined with pentostatin or cladribine for HCL (Else, Monica)

• Recombinant immunotoxin treatment of HCL
  o Development and mechanism of action of recombinant immunotoxins (FitzGerald, David)
  o Recombinant immunotoxins in HCL (Kreitman, Robert)
  o Immunotoxins with decreased immunogenicity and improved activity (Pastan, Ira)

• Into the future: New agents and targets
  o Targeting B cell lymphoma with nanoparticles bearing glycan ligands of CD22 (Paulson, James)
  o Flavopiridol targeting of B-cell malignancies and potential for HCL (Byrd, John)
  o Biomarkers in lymphoma (Wilson, Wyndham)

• Molecular characterization of HCL
  o Molecular variant of HCL with poor prognosis (Arons, Evgeny)
  o Molecular insight into the behavior of HCL by immunogenetic analysis (Forconi, Francesco)

• Goals of the HCL consortium: Improved research and patient access to information and trials (Grever, Michael)